Central Nervous System Market

BioNationLogin

Email

Password

I've forgotten my password!
Create an account here!

Therapeutic Areas

Competencies

Services

Devices

Central Nervous System

CentralNervous System Business News

neurogenetic pharmaceuticals announces studies showing its proprietary compound reduces brain plaque ... Today, 12:13 PM (GMT+1)
merck receives approval from fda for expanded indications for atypical antipsychotic medication saph ... Tue, 12:00 (GMT+1)
roche and remynd enter into a strategic alliance to develop first-in-class disease-modifying treatme ... Tue, 12:00 (GMT+1)
rexahn pharmaceuticals, inc. submits serdaxin phase iib protocol to fda for major depressive disorde ... Tue, 12:00 (GMT+1)
bedford laboratories to begin shipping sumaptriptan succinate injection, 6mg (base)/0.5 ml packaged ... Tue, 12:00 (GMT+1)
santhera and ipsen enter into licensing agreement for fipame-zole for the treatment of dyskinesia in ... Sep 3 2010
european commission issues positive decision for approval of seroquel xr as an add-on treatment of m ... Sep 2 2010

Central Nervous System Jobs

Find an open position today!

Profile

UCB's drug gets European approval

The UCB's antiepileptic agent Vimpat should be launched on the European market by this autumn. by Pierre-Philippe Luyet, PhD , 08/09/2008

Profile

Valeant and GSK sign collaboration deal worth up to $820 million

GSK obtains the exclusive worldwide development and commercialisation rights to Valeant Pharmaceuticals' epilepsy drugs. by Pierre-Philippe Luyet, PhD , 01/09/2008

Vanda received not approval letter from FDA

Following FDA's negative decision, Vanda pharmaceuticals decided to suspend all studies linked to its product iloperidone.30/07/2008

Alzheimer's treatment closer to market.

22/07/2008

Huntington's Disease and siRNA: Targeted Genetics Acquires Full Exclusive Rights

09/04/2008

EUR 8 M Upfront Payment For Newron To Purchase Hunter-Fleming

Newron aquires Hunter-Fleming in order to expand its early-stage compound portfolio for the treatment of neurodegenerative diseases.18/02/2008

Neurodegenerative Diseases: PharmatrophiX Gets 300,000 US$ For Drugs Development

30/01/2008

Exclusive Collaboration Between Addex And Merck

02/01/2008

Back to Zero

Solely in the United States, cocaine addiction continues to be an important public health problem with over 2.4 million of users in 2005. A novel mechanism of synaptic plasticity has been identified and may help to develop a treatment for drug addiction. 06/07/2007

CentralNervous System Headlines

CentralNervous System Partnerships

ROCHE HOLDING LTD REMYND	September 7th, 2010, Roche and reMYND announced that they had entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson's and Alzheimer's patients by inhibiting alpha-synuclein and tau toxicity.
MERCK AND CO INC ALECTOS THERAPEUTICS INC	August 11th, 2010, Alectos Therapeutics announced a research collaboration with Merck to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
BRISTOL-MYERS SQUIBB CO NEUROP CORPORATION	March 30th, 2010, NeurOp Corporation announced a collaboration with Bristol-Myers Squibb focused upon the development of NeurOp's proprietary small molecules for use in the treatment of major depression and other central nervous system disorders.